A comprehensive view of Combination Therapy. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bristol-Myers Squibb leads melanoma, lymphoma care innovation; BMS emphasizes R&D, global awareness for 300,000 melanoma, 600,000 lymphoma patients diagnosed annually
Published: September 16, 2024 by Industry Intelligence Inc.
NUBEQA plus ADT significantly reduces risk of progression or death in metastatic hormone-sensitive prostate cancer; Phase III ARANOTE trial results presented at ESMO 2024
Published: September 16, 2024 by Bayer AG
Imfinzi plus Imjudo shows 24% reduced death risk in advanced liver cancer; 19.6% of patients survive five years versus 9.4% with sorafenib in HIMALAYA Phase III trial
Published: September 16, 2024 by AstraZeneca AB
INTERNATIONAL PATENT: SANOFI, ELI LILLY AND COMPANY FILES APPLICATION FOR "ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES, ANTI-VEGFR-2 ANTIBODIES AND ANTI-PD1/PD-L1 ANTIBODIES"
Published: September 16, 2024 by U.S. Fed News
INTERNATIONAL PATENT: F. HOFFMANN-LA ROCHE AG, HOFFMANN-LA ROCHE INC. FILES APPLICATION FOR "COMBINATION THERAPY OF AN ANTI-EGFRVIII/ANTI-CD3 ANTIBODY AND AN TUMOR-TARGETED 4-1BB AGONIST"
Published: September 16, 2024 by U.S. Fed News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count